Politics
FDA Finalizes Guidance On ‘Unique Challenges’ Of Psychedelic Research And Schedules Hearing On Therapeutic Uses
The Food and Drug Administration (FDA) has issued finalized guidance to help researchers studying the therapeutic benefits of psychedelics navigate the “unique challenges” of such investigations. The agency also announced it will be holding a public hearing on psychedelic therapy issues in September.
“In recent years, interest in the therapeutic potential of psychedelic drugs has been increasing,” the FDA document published on Monday says.
“Drug development programs for psychedelic drugs are subject to the same regulations and same evidentiary standards for approval as other drug development programs,” the agency wrote. “However, designing clinical studies to evaluate the safety and effectiveness of these products presents a number of unique challenges.”
Psychedelics can “cause intense perceptual disturbances and alterations in consciousness that can last for several hours or days,” and can “have both rapid-onset and long-term benefits after only one or a few doses,” FDA said.
The guidance—titled “Psychedelic Drugs: Considerations for Clinical Investigations”—notes that psychedelics are an “an emerging area of drug development” and provides considerations that sponsors of research on substances like psilocybin, LSD and MDMA should take into account.
Among other areas, FDA is providing recommendations on how psychedelic studies handle issues such as chemistry, manufacturing, abuse potential and clinical pharmacology.
It notes that designing well-controlled studies on psychedelics can be particularly challenging due to the “often intense perceptual changes induced by the drugs.”
“This increases the potential for bias due to functional unblinding of patients, therapists, monitors, or raters,” the FDA document says. “Functional unblinding can lead to expectation bias in the patients who experience perceptual disturbances, or in those who observe them, which may lead to an expectation that the participant will experience clinical benefit; alternatively, those who receive a placebo and do not experience or observe a perceptual change may expect that the participant will not benefit.”
The final guidance builds on a draft version that FDA initially published in 2023 and comes months after President Donald Trump issued an executive order aimed at expanding and expediting research on the potential therapeutic benefits of psychedelics.
The agency said it took into account comments received in response to the draft version, and it is also accepting additional public feedback on the final document, FDA said in a Federal Register notice.
Meanwhile, FDA on Monday also announced that it will hold a public hearing on September 14 to “obtain feedback and perspectives on issues associated with the potential future therapeutic use of drug products containing a psychedelic drug substance in supervised and supportive settings.”
“The hearing will be conducted by a presiding officer, who will be accompanied by FDA panelists, including subject matter experts from the Center for Drug Evaluation and Research, as well as federal partner panelists,” the agency said in a Federal Register notice about the hearing.
FDA is inviting interested parties to apply to present about specific topics at the hearing, but it also made clear it is not inviting commentary about certain matters.
“FDA and our federal partners are interested in public input on the potential future therapeutic use of psychedelic drugs in supervised and supportive settings, including the following topics: (1) provider training and credentialing, (2) promotion of patient safety, (3) considerations for access, and (4) best practices for data collection and standardization,” it said.
“FDA is not seeking comment on the following topics: (1) the safety or effectiveness of any particular drug product, or the merits of any pending or anticipated application before the Agency; (2) the scheduling status of any substance under the Controlled Substances Act, which is addressed through separate statutory processes; (3) the legalization or decriminalization of psychedelic substances, or the merits of state or local programs authorizing their use, although FDA welcomes input on data collection from such programs as described above; (4) religious, ceremonial, or personal (non-medical) use of psychedelic substances; or (5) individual disputes, enforcement matters, or complaints regarding specific practitioners or entities. Comments and presentations addressing these topics may not be considered.”
FDA and the Department of Health and Human Services (HHS) in April announced steps that they say will help with “accelerating” therapeutic access to psychedelics for patients dealing with serious mental health conditions.
In May, a bipartisan coalition of 32 members of Congress sent a letter urging FDA to expedite ongoing reviews of psychedelic therapies.
This month, lawmakers filed a new bill that would require the Department of Defense (DOD) to evaluate how ongoing research on the therapeutic benefits of psilocybin could help members of the military.
A separate recently introduced bipartisan measure is intended to codify Trump’s psychedelics executive order into law.
A pending proposed amendment to the National Defense Authorization Act would extend a psychedelics research effort at DOD for an additional six years.
Photo elements courtesy of carlosemmaskype and Apollo.
